Nutritional Deficiencies in Patients with Thalassemia

Thalassemia is a group of inherited hemoglobin disorders that result in chronic anemia, often requiring regular blood transfusions and ironchelation therapy. While the hematologic aspects dominate clinical care, the metabolic demands of the disease and the sideeffects of treatment place patients at high risk for specific nutritional deficiencies. Recognizing and addressing these deficits is essential for growth, bone health, cardiac function, and overall quality of life.

Why Nutrition Matters in Thalassemia

Patients with thalassemia experience a combination of factors that alter nutrient balance:

• Increased basal metabolic rate due to chronic hemolysis and ineffective erythropoiesis.
• Frequent transfusions leading to iron overload, which interferes with the absorption and utilization of several micronutrients.
• Ironchelation agents (e.g., deferoxamine, deferasirox) that can cause gastrointestinal irritation and loss of minerals.
• Endocrine disturbances such as hypogonadism and hypothyroidism that modify nutrient requirements.
• Growth retardation especially in children, making adequate intake of protein, calories, and vitamins critical.

Key Micronutrient Deficiencies

1. Vitamin D and Calcium

Osteopenia and osteoporosis are common in thalassemia, with prevalence ranging from 3080% in adult cohorts. Contributing factors include marrow expansion, hormonal deficits, and iron deposition in boneremodeling cells.

Recommended approach:

• Serum 25hydroxyvitamin D measurement at least annually.
• Supplementation of 8001,000IU vitamin D3 daily, adjusted to reach serum levels >30ng/mL.
• Calcium intake of 1,0001,200mg/day from dairy or fortified sources.
• Weightbearing exercise and, when needed, bisphosphonate therapy.

2. Zinc

Zinc is vital for immune function, wound healing, and DNA synthesis. Studies report plasma zinc levels 2030% lower in thalassemia patients compared with controls. Chelation therapy may increase urinary zinc loss.

Suggested regimen: 30mg elemental zinc (as zinc gluconate or sulfate) daily, split into two doses to improve absorption.

3. Selenium

Selenium deficiency correlates with increased oxidative stress and poorer cardiac outcomes. Serum selenium concentrations are frequently suboptimal in transfusiondependent individuals.

Supplementation of 100200g selenium (as selenomethionine) per day is generally safe and may improve antioxidant capacity.

4. Vitamin E

Vitamin E protects erythrocyte membranes from lipid peroxidation. Low levels have been linked to increased hemolysis and organ damage.

Typical dosing: 400800IU mixedtocopherol daily, preferably with meals containing fat for better absorption.

5. Vitamin C

Vitamin C enhances iron absorption; however, in thalassemia patients with iron overload, high doses can exacerbate oxidative injury. Moderate intake (60100mg/day) is advised, primarily from fruit and vegetables, while avoiding large supplemental boluses.

6. Folate (Vitamin B9)

Rapid erythropoiesis depletes folate stores, leading to megaloblastic changes and impaired DNA synthesis. Folate deficiency can also mask B12 deficiency.

Recommended dose: 400g1mg folic acid daily, increased to 5mg during periods of intensified transfusion or growth spurts.

Macronutrient Considerations

Protein

Patients require 1.21.5g protein/kg body weight daily to support ongoing erythropoiesis and tissue repair. Highquality sources (lean meat, fish, dairy, legumes) are preferred.

Caloric Needs

Due to a higher basal metabolic rate, children and adolescents often need 1020% more calories than agematched peers. Energydense, nutrientrich foods (e.g., nuts, avocados, whole grains) should be incorporated.

Fatty Acids

Omega3 fatty acids (EPA/DHA) have antiinflammatory effects and may reduce cardiac remodeling. Aim for two servings of fatty fish per week or 1g of EPA/DHA supplement daily.

Impact of IronChelation Therapy on Nutrition

All three main chelatorsdeferoxamine (subQ infusion), deferiprone (oral), and deferasirox (oral)can cause gastrointestinal upset, hepatic enzyme elevation, and renal tubular dysfunction, potentially leading to loss of electrolytes (magnesium, potassium) and trace elements.

Monitoring plan:

• Baseline and periodic renalfunction tests (creatinine, electrolytes) and liver panels.
• Urinary magnesium and zinc checks every 612months.
• Adjust supplementation based on laboratory trends rather than routine highdose empiric therapy.

Practical Dietary Strategies

1. Balanced meals: Include a protein source, whole grain, and two vegetable servings at each main meal.
2. Fortified foods: Use vitamin Dfortified milk or orange juice; calciumfortified plant milks for those with lactose intolerance.
3. Limit ironrich nonheme foods when iron overload is severe; avoid excessive red meat and ironfortified cereals unless directed by a hematologist.
4. Hydration: Adequate fluid intake aids renal clearance of chelator metabolites and helps prevent nephrotoxicity.
5. Meal timing with chelators: Take oral chelators on an empty stomach and separate from calcium or zinc supplements by at least 2hours to avoid binding.

Monitoring and FollowUp

Effective management combines regular laboratory surveillance with individualized nutrition plans:

• Complete blood count and reticulocyte count every 36months.
• Serum ferritin, liver iron concentration (MRI), and cardiac T2* MRI annually.
• Vitamin D, calcium, zinc, selenium, and vitamin E levels at least once a year.
• Growth charts in children; bonedensity DXA scans every 23years.

Conclusion

Nutrition in thalassemia is a dynamic, multidisciplinary challenge. By identifying the most common deficienciesvitamin D, calcium, zinc, selenium, vitamin E, and folateand tailoring macronutrient intake to the elevated metabolic demands, clinicians can mitigate complications such as bone disease, cardiac dysfunction, and impaired immunity. Ongoing assessment, patient education, and coordination with hematology, endocrinology, and dietetics teams are the keystones of optimal longterm care.

References: World Health Organization. (2020). Guidelines on the Management of Thalassemia.; Cappellini, M.D., et al. (2021). Thalassaemia International Federation Recommendations.; Shamsi, M. et al. (2022). Nutritional status in transfusiondependent thalassemia. Blood Reviews, 46, 100874.